The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

@article{Klatzmann2015ThePO,
  title={The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases},
  author={David Klatzmann and Abul K Abbas},
  journal={Nature Reviews Immunology},
  year={2015},
  volume={15},
  pages={283-294}
}
Depletion of regulatory T (TReg) cells in otherwise healthy individuals leads to multi-organ autoimmune disease and inflammation. This indicates that in a normal immune system, there are self-specific effector T cells that are ready to attack normal tissue if they are not restrained by TReg cells. The data imply that there is a balance between effector T cells and TReg cells in health and suggest a therapeutic potential of TReg cells in diseases in which this balance is altered. Proof-of… CONTINUE READING
BETA

Figures and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 110 CITATIONS

Strategies for clinical trials in type 1 diabetes.

  • Journal of autoimmunity
  • 2016
VIEW 10 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Modulation of T cell responses by IL-2 and IL-2 complexes.

  • Clinical and experimental rheumatology
  • 2015
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 29 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 127 REFERENCES

Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus

Y Feng
  • Cell 158,
  • 2014

Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata

E Castela
  • JAMA Dermatol
  • 2014

Similar Papers

Loading similar papers…